石山德拉可以通过PI3K/AKT/mTOR信号通路在小鼠模型中缓解帕金森病的症状
Yawen Pan1, Mojinzi Chen2, Lulu Pan3
1Wenzhou TCM Hospital of Zhejiang Chinese Medical University, Wenzhou, 325000, People's Republic of China.
Neuropsychiatric disease and treatment
|October 28, 2024
概括
斯基桑德拉 (Sch D) 改善了帕金森病患者的运动功能和神经保护.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,其特点是运动缺陷和α-syn (α-syn) 的积累.
- 猛素 (mTOR) 信号通路的哺乳动物点在细胞过程中起着至关重要的作用,包括自,这与PD病变产生有关.
研究的目的:
- 在帕金森病 (PD) 的小鼠模型中研究石山德拉 (Schisandra Decoction,Sch D) 的神经保护作用.
- 阐明SchD作用的潜在机制,重点关注PI3K/AKT/mTOR信号通路及其对自和α-synuclein聚合的影响.
主要方法:
- 建立了一种1-甲基-4--1,2,3,6-四胺 (MPTP) 诱导的PD小鼠模型.
- 通过杆登,旋杆和开放场地测试来评估运动功能.
- 通过免疫组织化学,RT-PCR和西式涂抹,对神经保护标记物 (氨酸氧酶 - TH,α-synuclein) 和自标记物 (PTEN,PI3K,Akt,p-Akt,mTOR,p-mTOR,p70s6K,p62,LC3II/I) 的量化.
主要成果:
- 在PD小鼠中,SchD治疗显著改善了运动功能,这可以通过减少杆登时间和增加旋杆持续时间来证明.
- 施加SchD导致TH蛋白水平增加,PD小鼠大脑中α-synuclein清除增加.
- SchD逆转了MPTP诱导的PI3K/AKT/mTOR通路的改变,包括减少PTEN,增加PI3K/Akt/mTOR信号,以及正常化的LC3II/I和p62水平,表明自抑制.
结论:
- 在MPTP诱导的帕金森病小鼠模型中,斯基桑德拉 (Schisandra Decoction,Sch D) 显示出显著的神经保护作用.
- Sch D 改善了运动功能,并减少了α-synuclein 聚合,可能通过通过PI3K/AKT/mTOR通路抑制自.
- 这些发现表明,SchD的神经保护性质可能与其调节自和潜在地施加抗氧化作用的能力有关,这需要进一步调查其抗氧化能力.
相关概念视频
Parkinson's Disease: Treatment
227
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
227
Parkinson's Disease: Overview
486
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
486


